CLDN3 and hepatocellular carcinoma: Future investigations aimed at elucidating the distinct responses of HCC and normal hepatocyte cell lines to rVP1 treatment may provide the possibility of uncovering a therapeutic target that can minimize the detrimental effect of cancer therapy on normal hepatocytes.